WAYNE, Pa., May 7 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) today announced that its Sonomed division introduced two new
products at the American Society of Cataract & Refractive Surgery (ASCRS)
Symposium and Congress, which was being earlier this week in San Diego,
California.  The first product, a new ultrasound bio-microscope called the
UBM/35S, enables an ophthalmologist or ophthalmic surgeon to obtain an
accurate image of the front of the eye, including a cross-section of the
cornea.  In addition, Escalon received 510 (k) marketing clearance from the
FDA for its new B-Scan, the E-Z Scan(TM), an enhanced combination A-scan / B-
scan, and is launching this product in the U.S.
    "We are very excited about the potential for these two products,"
commented Richard J. DePiano, Chairman and Chief Executive Officer.  "The
UBM/35S is one of the few ophthalmic devices that enables you to see into the
front chamber of the eye.  While this will be particularly useful with
glaucoma patients as well as in refractive surgery, we also see significant
potential for its use in the insertion of implantable contact lenses.  In this
particular application, it is critical that the lenses are positioned properly
to avoid damage to the eye, including cataracts."
    Mr. DePiano added, "We are also pleased to announce the FDA approval of
our E-Z Scan(TM).  The product is an ophthalmic ultrasound device that is used
to take an image of the back of the eye, even when the view is impaired due to
conditions such as cataracts.  The product has aroused great interest at
various shows overseas and we are excited to commence marketing to the U.S.
With these new product additions we believe Sonomed will offer a full
portfolio of diagnostic tools for the ophthalmologist, enabling access to both
the front and back of the eye."

    About the UBM/35S
    The UBM/35S is a high frequency ultrasound device that features a
miniature lightweight probe, an interchangeable 35 or 50 MHz transducer, and
offers high sensitivity, high accuracy, high precision and high
reproducibility. Other features include dynamic movie recording, Vector A Scan
Measurement, Anterior Biometry to measure cornea thickness, lens thickness
with adjusted tissue velocity, Dual set calipers, Angle measurement, 2X
digital zoom with dual set calipers and 2X digital zoom with angle
measurement.  Escalon Medical's UBM/35S is specifically designed for the U.S.
market and utilizes high frequency technology supplied by Ophthalmologic
Technologies Inc. (OTI) of Ontario, Canada.  The collaborative product is
expected to be available in June 2004.

    About the E-Z Scan(TM)
    The E-Z Scan(TM) is an enhanced combination A-scan / B scan ophthalmic
ultrasound device used to image and diagnose retinal and other conditions at
the back of the eye.  E-Z Scan(TM), which replaces Sonomed's B5500 series,
offers a Color or Gray Scale B-Scan image with a full function A-Scan. The
device features a touch screen interface as well as a small and lightweight
design.

    Founded in 1987, Escalon develops, markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices.  Escalon seeks to further diversify its product line to achieve
critical mass in sales and take better advantage of Escalon's distribution
capabilities through internal product development, acquisitions or strategic
partnerships.  Escalon has headquarters in Wayne, Pennsylvania and
manufacturing operations in Long Island, New York and New Berlin, Wisconsin.

    Note:  This press release contains statements that are considered forward-
looking under the Private Securities Litigation Reform Act of 1995, including
statements about Escalon's future prospects.  They are based on Escalon's
current expectations and are subject to a number of uncertainties and risks,
and actual results may differ materially.  The uncertainties and risks include
whether Escalon is able to improve upon the operations of Escalon's business
units, generate cash and identify, finance and enter into business
relationships and acquisitions, uncertainties and risks related to new product
development, commercialization, manufacturing and market acceptance of new
products, marketing acceptance of existing products in new markets, research
and development activities, including failure to demonstrate clinical
efficacy, delays by regulatory authorities, scientific and technical advances
by Escalon or third parties, introduction of competitive products, third party
reimbursement and physician training as well as general economic conditions.
Further information about these and other relevant risks and uncertainties may
be found in Escalon's report on Form 10-K, and its other filings with the
Securities and Exchange Commission, all of which are available from the
Commission as well as other sources.

Link to this page: